InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Wednesday, 11/20/2019 8:30:48 AM

Wednesday, November 20, 2019 8:30:48 AM

Post# of 6042
News: $HTBX Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients

Prospectively Defined PD-L1 Positive Patients Achieved Median Overall Survival of 42 Months DURHAM, NC / ACCESSWIRE / November 20, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), presented additional positive Phase 2 interim top line data from Cohort A of the Company's Phase 2 trial of its...

In case you are interested HTBX - Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NHWK News